Abiopharma

New Form 8-K - Centessa Pharmaceuticals plc Filed: 2025-08-12 AccNo: 0001847903-25-000133 Size: 383 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

New Form 8-K - Korro Bio, Inc. Filed: 2025-08-12 AccNo: 0000950170-25-106910 Size: 404 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 10-Q - Adverum Biotechnologies, Inc. Filed: 2025-08-12 AccNo: 0001628280-25-039761 Size: 5 MB

New Form 8-K - Adverum Biotechnologies, Inc. Filed: 2025-08-12 AccNo: 0001628280-25-039759 Size: 222 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Research Shows Medtechs Prioritizing Site Collaboration and Data Quality

Passage Bio, Inc. - Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights

X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025

AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease

Altimmune Announces Second Quarter 2025 Financial Results and Business Update

Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for Registrational Trial ofAXPAXLI™ in NPDR

Tilray Expands Hemp-Derived Delta-9 THC Beverage Lineup with 10mg Drinks from Fizzy Jane’s and Happy Flower Brands

TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

NeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues